REGENERON PHARMACEUTICALS, INC.
 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) March 1, 2004 (February 27, 2004)

REGENERON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)
         
NEW YORK   0-19034   No. 13-3444607
 
(State or other jurisdiction
of incorporation) 		  (Commission
File Number) 		  (IRS Employer
Identification No.)
     
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY    10591-6707
 
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code (914) 347-7000

NOT APPLICABLE

(Former name or former address, if changed since last report)

 

 

INFORMATION TO BE INCLUDED IN REPORT

Item 5. Other Events and Regulation FD Disclosure.

     On February 27, 2004, the Company issued a press release, a copy of which is included as an exhibit to this filing.

Item 7. Financial Statements and Exhibits.

     (c) Exhibits

     99(a) Press Release dated February 27, 2004.

2

 

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     
  Regeneron Pharmaceuticals, Inc.
 
    
  By: /s/ Stuart Kolinski

Stuart Kolinski
  Vice President & General Counsel

Date: March 1, 2004

3